Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group

Finnish Leukemia Group, Aarne Kolonen, Marjatta Sinisalo, Heini Huhtala, Johanna Rimpiläinen, Hannele Rintala, Marja Sankelo, Elli Koivunen, Raija Silvennoinen, Riikka Räty, Tapani Ruutu, Liisa Volin, Kimmo Porkka, Esa Jantunen, Tapio Nousiainen, Taru Kuittinen, Karri Penttilä, Marja Pyörälä, Marjaana Säily, Pirjo KoistinenMarjut Kauppila, Maija Itälä-Remes, Hanna Ollikainen, Auvo Rauhala, Veli Kairisto, Tarja-Terttu Pelliniemi, Erkki Elonen

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalEuropean Journal of Haematology
Volume109
Issue number3
Pages (from-to)257-270
Number of pages14
ISSN0902-4441
DOIs
Publication statusPublished - Sept 2022
MoE publication typeA1 Journal article-refereed

Fields of Science

  • allogeneic stem cell transplant
  • AML
  • induction chemotherapy
  • long-term follow-up
  • measurable residual disease
  • nationwide
  • randomized
  • survival
  • YOUNGER PATIENTS
  • CLASSIFICATION
  • CHEMOTHERAPY
  • ADULTS
  • STANDARD
  • THERAPY
  • 3122 Cancers

Cite this